Thrombosis remains the leading cause of morbidity and mortality for patients (pts) with polycythemia vera (PV), yet PV clinical trials are not powered to identify interventions that improve thrombosis-free survival (TFS). Such trials are infeasible in a contemporary PV cohort, even when selecting high-risk pts based on Age >60 and thrombosis history, because thousands of patients would be required for a short-term study to meet TFS endpoint. To address this problem, we used artificial intelligence and machine learning (ML) to dynamically predict near-term (1-year) thrombosis risk in PV pts with high sensitivity and positive predictive value (PPV) to enhance pts selection. Our automation-driven data extraction methods yielded more than 16 million data elements across 1,448 unique variables (parameters) from 11,123 clinical visits for 470 pts. Using the AutoGluon framework, the Random Forest ML classification algorithm was selected as the top performer. The full (309-parameter) model performed very well (F1=0.91, AUC=0.84) when compared with the current ELN gold-standard for thrombosis risk stratification in PV (F1=0.1, AUC=0.39). Parameter engineering, guided by Gini feature importance identified the 21 parameters (top-21) most important for accurate prediction. The top-21 parameters included known, suspected and previously unappreciated thrombosis risk factors. To identify the minimum number of parameters required for the accurate ML prediction, we tested the performance of every possible combination of 3-9 parameters from top-21 (>1.6M combinations). High-performing models (F1> 0.8) most frequently included age (continuous), time since dx, time since thrombosis, complete blood count parameters, blood type, body mass index, and JAK2 mutant allele frequency. Having trained at tested over 1.6M practical ML models with a feasible number of parameters (3-9 parameters in top-21 most predictive), it is clear that study cohorts of patients with PV at high near-term thrombosis risk can be identified with high enough sensitivity and PPV to power a clinical trial for TFS. Further validation with external, multicenter cohorts is ongoing to establish a universal ML model for PV thrombosis that would facilitate clinical trials aimed at improving TFS.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board of Weill Cornell Medicine approved this study. Protocol # 19-12021151

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors